Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies? World J Gastroenterol 2017; 23(15): 2640-2650 [PMID: 28487601 DOI: 10.3748/wjg.v23.i15.2640]
Corresponding Author of This Article
Federica Cavalcoli, MD, Gastroenterology and Endoscopic Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milano, Italy. cavalcoli.federica@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 21, 2017; 23(15): 2640-2650 Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2640
Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?
Federica Cavalcoli, Emanuele Rausa, Dario Conte, Antonio Federico Nicolini, Sara Massironi
Federica Cavalcoli, Dario Conte, Sara Massironi, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
Federica Cavalcoli, Dario Conte, Postgraduate School of Gastroenterology, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milan, Italy
Emanuele Rausa, Department of Colorectal Diseases, St. Vincent’s University Hospital, Elm Park, Dublin 8, Dublin, Ireland
Antonio Federico Nicolini, Department of Interventional Radiology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
Author contributions: Cavalcoli F and Massironi S planned the work; Rausa E performed the literature search; Rausa E and Cavalcoli F wrote the first draft of the manuscript; Cavalcoli F and Rausa E edited the subsequent versions of the manuscript; Conte D, Nicolini AF and Massironi S critically revised the manuscript for relevant intellectual content; Finally, all the authors read and approved the final manuscript.
Conflict-of-interest statement: The authors declare no conflict of interest related to this publication.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Federica Cavalcoli, MD, Gastroenterology and Endoscopic Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milano, Italy. cavalcoli.federica@gmail.com
Telephone: +39-2-55033444 Fax: +39-2-55033644
Received: February 7, 2017 Peer-review started: February 10, 2017 First decision: February 23, 2017 Revised: March 11, 2017 Accepted: March 20, 2017 Article in press: March 20, 2017 Published online: April 21, 2017 Processing time: 81 Days and 15.1 Hours
Core Tip
Core tip: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) frequently present with distant metastases. In the last years, a number of treatment has become available for advanced GEP-NENs and the optimal management for these patients remains to be established. While systemic medical therapies and peptide receptor radionuclide therapy represent effective options, they are usually palliative whereas liver-directed treatments often represent the only possibly curative therapy, even if not supported by prospective trials. Considering the lack of randomized trials comparing locoregional treatments in advanced GEP-NEN, clinical judgment remains key to set the most appropriate therapeutic pathway. Prospective data may lead to more personalized and optimized treatments.
